SlideShare uma empresa Scribd logo
1 de 76
Protein Synthesis Inhibitors  Claro M. Isidro M.D.
Protein Synthesis ,[object Object],[object Object],[object Object],[object Object],[object Object]
Summary ,[object Object]
 
Protein Synthesis Inhibitors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
I.  AMINOGLYCOSIDES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
I. AMINOGLYCOSIDES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
I. AMINOGLYCOSIDES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
I. AMINOGLYCOSIDES ,[object Object],[object Object],[object Object],[object Object],[object Object]
I. AMINOGLYCOSIDES ,[object Object],[object Object],[object Object],[object Object],[object Object]
I. AMINOGLYCOSIDES ,[object Object],[object Object],[object Object],[object Object],[object Object]
I. AMINOGLYCOSIDES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
STREPTOMYCIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
GENTAMICIN ,[object Object],[object Object],[object Object]
Gentamicin ,[object Object],[object Object]
GENTAMICIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
TOBRAMYCIN ,[object Object],[object Object],[object Object],[object Object],[object Object]
AMIKACIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
NETILMICIN ,[object Object],[object Object],[object Object]
KANAMYCIN & NEOMYCIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
KANAMYCIN & NEOMYCIN ,[object Object],[object Object],[object Object],[object Object],[object Object]
SPECTINOMYCIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
II.TETRACYCLINES : ,[object Object],[object Object],[object Object],[object Object],[object Object]
II. TETRACYCLINES ,[object Object],[object Object],[object Object]
II. TETRACYCLINES ,[object Object],[object Object],[object Object],[object Object]
II. TETRACYCLINES ,[object Object],[object Object],[object Object],[object Object]
II. TETRACYCLINES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
II. TETRACYCLINES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
II. TETRACYCLINES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
THE 50 S INHIBITORS: ,[object Object],[object Object],[object Object],[object Object],[object Object]
I. CHLORAMPHENICOL ,[object Object],[object Object]
I. CHLORAMPHENICOL ,[object Object],[object Object],[object Object]
I. CHLORAMPHENICOL ,[object Object],[object Object],[object Object]
I. CHLORAMPHENICOL ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
I. CHLORAMPHENICOL ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
II.  MACROLIDES: ,[object Object],[object Object],[object Object],[object Object]
II. MACROLIDES ,[object Object],[object Object],[object Object],[object Object]
II. MACROLIDES ,[object Object],[object Object],[object Object],[object Object]
II. MACROLIDES ,[object Object],[object Object],[object Object],[object Object]
Erythromycin ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Erythromycin ,[object Object],[object Object],[object Object]
Clarithromycin ,[object Object],[object Object],[object Object],[object Object],[object Object]
Azithromycin ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Azithromycin ,[object Object],[object Object],[object Object]
III.  CLINDAMYCIN / LINCOMYCIN ,[object Object],[object Object],[object Object],[object Object]
III.  CLINDAMYCIN / LINCOMYCIN ,[object Object],[object Object],[object Object],[object Object]
III.  CLINDAMYCIN / LINCOMYCIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CLINDAMYCIN ,[object Object],[object Object],[object Object],[object Object]
CLINDAMYCIN ,[object Object],[object Object],[object Object],[object Object],[object Object]
STREPTOGRAMINS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
STREPTOGRAMINS ,[object Object],[object Object],[object Object],[object Object],[object Object]
OXAZOLADINONES: Linezolid (Zyvox) ,[object Object],[object Object],[object Object],[object Object],[object Object]
METABOLIC INHIBITORS Claro M. Isidro M.D.
SULFONAMIDES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
SULFONAMIDES ,[object Object],[object Object],[object Object],[object Object]
SULFONAMIDES  ,[object Object],[object Object],[object Object],[object Object],[object Object]
SULFONAMINDES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
SULFONAMIDES ,[object Object],[object Object],[object Object],[object Object]
SULFONAMIDES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
SULFONAMIDE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
SULFONAMIDES  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
TRIMETOPRIM SULFAMETHOXAZOLE  (CO-TRIMOXAZOLE) ,[object Object],[object Object],[object Object],[object Object],[object Object]
CO-TRIMOXAZOLE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CO-TRIMOXAZOLE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
NUCLEIC ACID SYNTHESIS INHIBITORS ,[object Object],[object Object],[object Object],[object Object]
Fluoroquinolones ,[object Object],[object Object],[object Object]
Fluoroquinolones ,[object Object],[object Object],[object Object],[object Object],[object Object]
Fluoroquinolones  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CIPROFLOXACIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
LEVOFLOXACIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fluoroquinolones  ,[object Object],[object Object],[object Object],[object Object],[object Object]
Fluoroquinolones ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Mais conteúdo relacionado

Mais procurados (20)

Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
Macrolides antibiotics (with lincosamide)
Macrolides antibiotics (with lincosamide) Macrolides antibiotics (with lincosamide)
Macrolides antibiotics (with lincosamide)
 
Tetracycline
TetracyclineTetracycline
Tetracycline
 
Tetracyclines
Tetracyclines Tetracyclines
Tetracyclines
 
Macrolide antibiotics
Macrolide antibioticsMacrolide antibiotics
Macrolide antibiotics
 
Penicillin
PenicillinPenicillin
Penicillin
 
Pharmacology -Protein synthesis inhibitors 2
Pharmacology -Protein synthesis inhibitors 2Pharmacology -Protein synthesis inhibitors 2
Pharmacology -Protein synthesis inhibitors 2
 
Antimycobacterials Drugs
Antimycobacterials Drugs Antimycobacterials Drugs
Antimycobacterials Drugs
 
Macrolide antibiotics
Macrolide antibioticsMacrolide antibiotics
Macrolide antibiotics
 
Antifungal drugs
Antifungal drugsAntifungal drugs
Antifungal drugs
 
Beta lactam antibiotics
Beta lactam antibioticsBeta lactam antibiotics
Beta lactam antibiotics
 
Carbapenems
CarbapenemsCarbapenems
Carbapenems
 
Anti tubercular drugs
Anti tubercular drugsAnti tubercular drugs
Anti tubercular drugs
 
Penicillins (VK)
Penicillins (VK)Penicillins (VK)
Penicillins (VK)
 
Antiobiotics - Macrolides and miscellaneous
Antiobiotics - Macrolides and miscellaneousAntiobiotics - Macrolides and miscellaneous
Antiobiotics - Macrolides and miscellaneous
 
Beta lactam antibiotics
Beta lactam antibioticsBeta lactam antibiotics
Beta lactam antibiotics
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
Glycopeptide ab.
Glycopeptide ab.Glycopeptide ab.
Glycopeptide ab.
 
Broad spectrum antibiotic tetracycline converted
Broad spectrum antibiotic tetracycline convertedBroad spectrum antibiotic tetracycline converted
Broad spectrum antibiotic tetracycline converted
 
Macrolide antibiotics.pptx
Macrolide antibiotics.pptxMacrolide antibiotics.pptx
Macrolide antibiotics.pptx
 

Destaque

Destaque (7)

Protien synthesis inhibitors by dr.elza
Protien  synthesis  inhibitors by dr.elzaProtien  synthesis  inhibitors by dr.elza
Protien synthesis inhibitors by dr.elza
 
Protein synthesis inhibitors
Protein synthesis inhibitorsProtein synthesis inhibitors
Protein synthesis inhibitors
 
Antimicrobial 3 protein synthesis inhibitors
Antimicrobial 3 protein synthesis inhibitorsAntimicrobial 3 protein synthesis inhibitors
Antimicrobial 3 protein synthesis inhibitors
 
Protein synthesis inhibitors
Protein synthesis inhibitorsProtein synthesis inhibitors
Protein synthesis inhibitors
 
Pharmacology - Protein Synthesis Inhibitor
Pharmacology - Protein Synthesis InhibitorPharmacology - Protein Synthesis Inhibitor
Pharmacology - Protein Synthesis Inhibitor
 
3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)
3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)
3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)
 
Newer antibiotics and uses
Newer antibiotics and usesNewer antibiotics and uses
Newer antibiotics and uses
 

Semelhante a Psi 2

inhibitor of bacterial Protein synthesis.ppt
inhibitor of bacterial Protein synthesis.pptinhibitor of bacterial Protein synthesis.ppt
inhibitor of bacterial Protein synthesis.pptDr Ndayisaba Corneille
 
Antimycobacterial drugs.ppt
Antimycobacterial drugs.pptAntimycobacterial drugs.ppt
Antimycobacterial drugs.pptAbwoneKenneth
 
classaminoglycosides2-150525094713-lva1-app6891.pdf
classaminoglycosides2-150525094713-lva1-app6891.pdfclassaminoglycosides2-150525094713-lva1-app6891.pdf
classaminoglycosides2-150525094713-lva1-app6891.pdfProf. Dr Pharmacology
 
Class aminoglycosides 2
Class aminoglycosides 2Class aminoglycosides 2
Class aminoglycosides 2Raghu Prasada
 
systemic anti-microbials in periodontal therapy
systemic anti-microbials in periodontal therapysystemic anti-microbials in periodontal therapy
systemic anti-microbials in periodontal therapyMehul Shinde
 
3,Antibiotics that inhibit bacterial protein synthesis.ppt
3,Antibiotics that inhibit bacterial protein synthesis.ppt3,Antibiotics that inhibit bacterial protein synthesis.ppt
3,Antibiotics that inhibit bacterial protein synthesis.pptssusera7496f
 
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptxCHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptxSamuelAgboola11
 
TB and Leprosy.pptx
TB and Leprosy.pptxTB and Leprosy.pptx
TB and Leprosy.pptxsapnabohra2
 
Aminoglycoside and macrolide antibiotics
Aminoglycoside  and macrolide  antibioticsAminoglycoside  and macrolide  antibiotics
Aminoglycoside and macrolide antibioticsMangeshBansod2
 
protein synthesis inhibitors.pptx
protein synthesis inhibitors.pptxprotein synthesis inhibitors.pptx
protein synthesis inhibitors.pptxarslan537537hyf
 
Anti fungal (amphotericin b)
Anti fungal (amphotericin b)Anti fungal (amphotericin b)
Anti fungal (amphotericin b)Zafar Ali Bangash
 
ANTI AMOEBIC DRUGS ( drugs against amoebic action)
ANTI AMOEBIC DRUGS ( drugs against amoebic action)ANTI AMOEBIC DRUGS ( drugs against amoebic action)
ANTI AMOEBIC DRUGS ( drugs against amoebic action)Teena42750
 

Semelhante a Psi 2 (20)

inhibitor of bacterial Protein synthesis.ppt
inhibitor of bacterial Protein synthesis.pptinhibitor of bacterial Protein synthesis.ppt
inhibitor of bacterial Protein synthesis.ppt
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
Antimycobacterial drugs.ppt
Antimycobacterial drugs.pptAntimycobacterial drugs.ppt
Antimycobacterial drugs.ppt
 
classaminoglycosides2-150525094713-lva1-app6891.pdf
classaminoglycosides2-150525094713-lva1-app6891.pdfclassaminoglycosides2-150525094713-lva1-app6891.pdf
classaminoglycosides2-150525094713-lva1-app6891.pdf
 
Class aminoglycosides 2
Class aminoglycosides 2Class aminoglycosides 2
Class aminoglycosides 2
 
Antibiotics
AntibioticsAntibiotics
Antibiotics
 
systemic anti-microbials in periodontal therapy
systemic anti-microbials in periodontal therapysystemic anti-microbials in periodontal therapy
systemic anti-microbials in periodontal therapy
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
3,Antibiotics that inhibit bacterial protein synthesis.ppt
3,Antibiotics that inhibit bacterial protein synthesis.ppt3,Antibiotics that inhibit bacterial protein synthesis.ppt
3,Antibiotics that inhibit bacterial protein synthesis.ppt
 
Rational use of Antibiotics
Rational use of AntibioticsRational use of Antibiotics
Rational use of Antibiotics
 
Antifungal Drugs 3.ppt
Antifungal Drugs 3.pptAntifungal Drugs 3.ppt
Antifungal Drugs 3.ppt
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptxCHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
 
TB and Leprosy.pptx
TB and Leprosy.pptxTB and Leprosy.pptx
TB and Leprosy.pptx
 
Aminoglycoside and macrolide antibiotics
Aminoglycoside  and macrolide  antibioticsAminoglycoside  and macrolide  antibiotics
Aminoglycoside and macrolide antibiotics
 
16. antifungal
16. antifungal16. antifungal
16. antifungal
 
protein synthesis inhibitors.pptx
protein synthesis inhibitors.pptxprotein synthesis inhibitors.pptx
protein synthesis inhibitors.pptx
 
Anti fungal (amphotericin b)
Anti fungal (amphotericin b)Anti fungal (amphotericin b)
Anti fungal (amphotericin b)
 
ANTI AMOEBIC DRUGS ( drugs against amoebic action)
ANTI AMOEBIC DRUGS ( drugs against amoebic action)ANTI AMOEBIC DRUGS ( drugs against amoebic action)
ANTI AMOEBIC DRUGS ( drugs against amoebic action)
 

Mais de MD Specialclass

Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...MD Specialclass
 
Git diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionGit diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionMD Specialclass
 
Getting ahead of headaches
Getting ahead of headachesGetting ahead of headaches
Getting ahead of headachesMD Specialclass
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL MD Specialclass
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL MD Specialclass
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinomaMD Specialclass
 
Normal sleep and sleep disorders
Normal sleep and sleep disordersNormal sleep and sleep disorders
Normal sleep and sleep disordersMD Specialclass
 
Toxic and drug induced hepatitis
Toxic and drug induced hepatitisToxic and drug induced hepatitis
Toxic and drug induced hepatitisMD Specialclass
 
Complications of cirrhosis
Complications of cirrhosisComplications of cirrhosis
Complications of cirrhosisMD Specialclass
 

Mais de MD Specialclass (20)

Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
 
Git diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionGit diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutrition
 
Getting ahead of headaches
Getting ahead of headachesGetting ahead of headaches
Getting ahead of headaches
 
Acute brain attack 911
Acute brain attack  911Acute brain attack  911
Acute brain attack 911
 
Hema intro anemia
Hema intro anemiaHema intro anemia
Hema intro anemia
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL
 
Fever & id diet final
Fever & id diet finalFever & id diet final
Fever & id diet final
 
Eating disorders
Eating disordersEating disorders
Eating disorders
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinoma
 
Eating disorders
Eating disordersEating disorders
Eating disorders
 
Normal sleep and sleep disorders
Normal sleep and sleep disordersNormal sleep and sleep disorders
Normal sleep and sleep disorders
 
Tic disorder
Tic disorderTic disorder
Tic disorder
 
Thyroid
ThyroidThyroid
Thyroid
 
Dermatology dr.n.ramos
Dermatology   dr.n.ramosDermatology   dr.n.ramos
Dermatology dr.n.ramos
 
Tic disorder
Tic disorderTic disorder
Tic disorder
 
Toxic and drug induced hepatitis
Toxic and drug induced hepatitisToxic and drug induced hepatitis
Toxic and drug induced hepatitis
 
Pancreatic disease
Pancreatic diseasePancreatic disease
Pancreatic disease
 
Liver disease
Liver diseaseLiver disease
Liver disease
 
Complications of cirrhosis
Complications of cirrhosisComplications of cirrhosis
Complications of cirrhosis
 

Último

Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...saminamagar
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformKweku Zurek
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingArunagarwal328757
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxvirengeeta
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...saminamagar
 

Último (20)

Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, Pricing
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptx
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptx
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
 

Psi 2

  • 1. Protein Synthesis Inhibitors Claro M. Isidro M.D.
  • 2.
  • 3.
  • 4.  
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.
  • 51.
  • 52.
  • 53. METABOLIC INHIBITORS Claro M. Isidro M.D.
  • 54.
  • 55.  
  • 56.
  • 57.
  • 58.
  • 59.
  • 60.
  • 61.
  • 62.
  • 63.
  • 64.
  • 65.
  • 66.
  • 67.
  • 68.
  • 69.
  • 70.
  • 71.
  • 72.
  • 73.
  • 74.
  • 75.  
  • 76.

Notas do Editor

  1. This slide shows the different site of action of protein synthesis inhibitors
  2. Buy AT 30, CELLS at 50 Protein Synthesis Inhibitors 30 S INHIBITORS Aminoglycoside Tetracyclines 50 S INHIBITORS Chloramphenicol Macrolides Clindamycin Streptogramins Oxazoladinones
  3. I. Older Aminoglycosides: Is a large group of bactericidal drug Streptomycin Kanamycin Newer Aminoglycosides: Gentamicin Sisomicin Neomycin Paromomycin Amikacin Netilmicin Tobramycin
  4. Antimicrobial Spectrum: Gram (-) Aerobic Bacilli Beta-lactamase producers: Staph. aureus N. gonorrhea Mycobacteria
  5. Mechanism of action The initial event is passive diffusion via porin across the outer membrane. Drug is then actively transported across the cell membrane into the cytoplasm by an oxygen dependent process. The transmembrane electrochemical gradients supplies the energy for this process and transport is coupled by proton pump. Low extracellular pH and anaerobic conditions inhibit the transport by reducing the gradient. The transport may be enhanced by cell wall active drugs, such as penicillin and vancomycin. This enhancement may the basis of the synergism. Once inside the cell it binds the 30S subunit. Protein synthesis is inhibited by atleast 3 ways: Interferes with the intiation complex of peptide formation They induce misreading of mRNA, causing incorporation of incorrect amino acids into the peptide resulting in a non-functional or toxic protein They cause a breakup of polysomes into non-functional monosomes These activities occurs more or less simultaneously, and the overall effect is irreversible and lethal for the cells
  6. Three principal mechanism of resistance. Microorganism develops by: The microorganism produces a transferase enzyme or enzyme that inactivate the aminoglycoside by adenylation, acetylation, or phosphorylation. This the principal type of resistance encountered. Impaired entry of the drug into the cell through cell surface alteration. This may be genotypic. Resulting from mutation or deletion of porin proteins. Or phenotypic, resulting from condition under which the oxygen dependent transport process is not functional The receptor protein on the 30S ribosome may be deleted or altered as a result of mutation
  7. Kinetics Absorbed very poorly from intact gastrointestinal tract They are highly polar compounds that do not enter the cells readily. They are largely excluded from the CNS and the eye. Not significantly metabolize Primarilly excreted unchanged through glumerular filtration dosage adjustment must be observed to avoid accumulation of drug and toxicity in patient with renal insufficiency
  8. Clinical Uses: severe gram (-) enteric bacteria especially when there is suspicion of sepsis Almost always used in combination with a beta-lactam antibiotic to extend coverage to include potential gram (+) pathogens and to take advatage of the synergism between the two classes of drugs. Penicillin aminoglycoside combinations also are used to achieve bactericidal activity in treatment of enterococcal endocarditis and to shorten duration of therapy for viridans streptococcal and staphylococcal endocarditis Mycobacterial infections Which aminoglycoside and what dose should be used depend upon the infection being treated and susceptibility of the isolate
  9. Toxicity All aminoglycoside are ototoxic and nephrotoxic Ototoxicity and nephrotoxicity are more likely encountered when therapy is continued for more than five days Concurrent use with loop diuretics like ethcrynic acid can potentiate ototoxicity and should be avoided Ototoxicity can manifest itself as auditory damage resulting in tinnitus and high frequency hearing, loss. Neomycin, Kanamycin and amikacin are most ototoxic Or it can also manifest as vestibular damage evident by vertigo ataxia and loss of balance. Streptomycin, Gentamicin are most vestibulotoxic Concurrent used of nephrotoxic agent can potentiate nephrotoxicity and should be avoided Neomycin, Tobramycin, Gentamicin are the most nephrotoxic
  10. Streptomycin Ribosomal resistance to this agent develops readily, limiting its role as a single agent mainly used as a second line agent for treatment of tuberculosis given at 0.5-1 g/d , IM or IV. usually given in drug combination to prevent emergence of resistance. In plague, tularemia and sometimes brucellosis, 1 g/d (15 mg/kg/d for children) IM or IV + oral tetracycline + Penicillin; effective for enterococcal endocarditis and 2 week therapy of viridans streptococcal endocarditis. can cause fever, skin rashes and other allergic reactions, pain at the injection site, vestibular dysfunction-most serious toxic effect if given during pregnancy, can cause deafness in the newborn
  11. Gentamicin At present gentamicin is employed mainly in severe infections (sepsis and pneumonia) caused by gram negative bacteria that are likely resistant to other drugs especially pseudomonas, enterobacter, serratia, proteus, and klebsiella. Used in combination with cephalosporin or a penicillin Given at 5-6 mg/kg/d I300V in three equal doses Concurrently used with Penicillin G for bactericidal activity in endocarditis due to viridans streptococci or enterococci and in combn with Nafcillin in selected cases of staphylococcal endocarditis Neither gentamicin nor any other aminoglycosides should be used for single agent therapy of pneumonia because penetration of infected lung tissue is poor and local condition of low pH and low oxygen contribute to poor activity
  12. Gentamicin sulfate 0.1% - 0.3% cream, ointment – for the treatment of infected burns, wounds, or skin lesions and the prevention of intravenous catheter infections. Topical gentamicin is partly inactivated by purulent exudates Ten milligrams can be injected subconjunctivally for treatment of ocular infections Nephrotoxicity is reversible and usually mild Irreversible ototoxicity manifested as vestibular dysfunction hypersensitivity reactions are uncommon
  13. Tobramycin antimicrobrial spectrum and pharmacokinetic properties virtually identical to gentamicin given at 5-6 mg/kg IM or IV into three equal amounts q 8 hours. Blood levels should be monitored in renal insufficiency Slightly more active against pseudomonas but not to E. faecium Ototoxic and nephrotoxic
  14. Amikacin Semisynthetic derivative of kanamycin Resistant to many inactivating enzymes. Therefore can be employed against some organism resistant to gentamicin and tobramycin Strains of multi-drug M. tuberculosis including streptomycin-resistant strains are usually susceptible. Given at 7.5 – 15 mg/kg/day as once daily or 2-3x weekly Serum concentrations should be monitored Nephrotoxic and ototoxic (auditory portion of CN VIII)
  15. Netilmicin shares many characteristics with gentamicin and tobramycin dosage and the routes of administration are the same , completely therapeutically interchangeable with gentamicin or tobramycin and has similar toxicities
  16. Kanamycin & Neomycin Paromomycin also a member of this group. Used for bowel preparation for elective surgery There is complete cross-resistance between kanamycin and neomycin Not significantly absorbed from the GIT; excretion of any absorbed drug is mainly through GF into the urine Too toxic for parenteral use, now limited to topical and oral use Solutions 1-5 mg/ml- used on infected surfaces or injected into joints, pleural cavity, tissue spaces or abscess cavities where infection is present. ( 15 mg/kg/d) Ointments (Neomycin-Polymyxin-Bacitracin combination); applied to infected skin lesions or in the nares for suppression of staphylococci
  17. In preparation for elective bowel surgery, 1 g of Neomycin given orally q 6-8 hours + 1 g of erythromycin base; Paromomycin, 1 g q 6 hours orally for 2 weeks; effective in intestinal amebiasis Nephrotoxic and ototoxic ( Auditory dysfunction) Sudden absorption of postoperatively instilled kanamycin from the peritoneal cavity (3-5 g) has resulted in curare-like neuromuscular blockade and respiratory arrest (Calcium gluconate and neostigmine can act as antidotes) Prolonged application to skin and eyes has resulted to severe allergic reactions
  18. Spectinomycin Chemically related to the aminoglycosides Binds at the 30 S subunit (bacteriostatic) Dispensed as the dihydrochloride pentahydrate for IM injection Used almost solely as an alternative treatment for gonorrhea in patients who are allergic to penicillin or whose gonococci are resistant to other drugs Single dose of 2 g (40 mg/kg) Can cause pain at the injection site , occasionally fever and nausea Nephrotoxicity and anemia – rare
  19. II.TETRACYCLINES: Short Acting: Tetracyline, Oxytetracycline, Chlortetracycline Intermediate Acting: Demeclocycline, Methacycline Long Acting: Doxycycline, Minocycline
  20. Antimicrobial Spectrum: Rickettsia, V. cholera, M. pneumonia, Chlamydia, Shigella, H. pylori, P.tularensis, P.pseudomallei, Brucella, Psittacosis, Borrelia Minocycline – carrier state of Meningococcal infections, N. asteroides, N. gonnorhea
  21. Mechanism of Action: Enter microorganisms in part by passive diffusion and in part by an energy-dependent process of active transport Binds to 30 S, blocking the binding of amino-acyl trna to the acceptor site and prevents the addition of amino acids to the growing peptide Bacteriostatic
  22. There are three mechanism of resistance decreased intracellular accumulation due to impaired influx or increased efflux by an active transport protein pump ribosome protection due to production of proteins that interfere with tetracycline binding to the ribosome enzymatic inactivation
  23. Kinetics Distributed widely to tissue and body fluids except for CSF Absorption occurs mainly in the upper small intestine and is impaired by food (except Doxycyline and Minocycline) Must not be taken with dairy products or antacids Cross placenta, excreted in milk As result of chelation with Ca, they are bound to and damage growing bones and teeth Carbamazepine, phenytoin, barbiturates, and chronic alcohol ingestion may shorten the half-life of doxycycline Excreted mainly in bile and urine (Doxycycline fecally eliminated; can be used in renal failure)
  24. Clinical Uses: DOC in infection with M. pneumoniae, chlamidiae,ricketsiae,and spirochetes. No longer recommended for gonococcal disease due to resistance. Usually use in combination aminoglycosides Can also be used in Borrelia burgdorfi (Lyme disease), Chlamydia, Ureaplasma, M. pneumonia, Acne, Tularemia, Cholera, Leptospirosis, Protozoal infections Minocycline, 200 mg orally daily for 5 days – can eradicate the meningococcal carrier state Demeclocycline – inhibits the action of ADH in the renal tubule and has been used in the treatment of inappropriate secretion of ADH or similar peptides by certain tumors
  25. Clinical Uses: Tetracyclines – 250-500 mg 4x/day adults; 20-40 mg/kg/d-children above 8 y/o Demeclocycline and Methacycline -> 600 mg daily Doxycyline and Minocycline -> 100 mg 1-2x/d Toxicity: Renal toxicity, local tissue toxicity, photosensitization, GI distress, discolors teeth, inhibits bone growth in children, potentially teratogenic, hepatotoxicity, vestibular toxicity
  26. THE 50 S INHIBITORS: CHLORAMPHENICOL MACROLIDES CLINDAMYCIN/LINCOMYCIN STREPTOGRAMINS OXAZOLADINONES
  27. I. CHLORAMPHENICOL Bactericidal – H. influenze, N. meningitides, B. fragilis Bacteriostatic – S. epidermidis, S. aureus, , M. pneumonia, L. monocytogenes, C.diphtheria, L. multocida, Salmonella sp., Shigella sp., E. coli, Rickettsia, Anaerobes
  28. MECHANISM OF ACTION: attaches at P sites of 50 S subunit of microbial ribosomes and inhibits functional attachment of amino-acyl end of AA-t-RNA to 50 S subunit inhibits peptidyl transferase step
  29. SPECTRUM: broad spectrum antibiotic more effective than Tetracyclines against Typhoid Fever and other Salmonella infections
  30. KINETICS: well absorbed after oral administration; usual dosage is 50-100 mg/kg/d Chloramphenicol succinate used for parenteral administration is highly water soluble distributed into total body water excellent penetration into CSF, ocular and joint fluids rapidly excreted in urine, 10% as chloramphenicol; 90% as glucuronide conjugate; small amount of active drug is excreted into bile or feces systemic dosage need not be altered in renal insufficiency but must be reduced markedly in hepatic failure Newborns less than a week old and premature infants also clear Chloramphenicol less well, dosage should be reduced at 25 mg/kg/d.
  31. CLINICAL USES: Meningitis, Rickettsia, Salmonella and anaerobic infections; ineffective against chlamydial infections occasionally used topically in the treatment of eye infections for its well penetration to ocular tissues and the aqueous humor ADVERSE EFFECTS: GIT, oral or vaginal candidiasis, irreversible aplastic anemia, reversible bone marrow depression, Gray Baby Syndrome New born infants lack an effective glucoronic acid conjugation mechanism for degradation and detoxification of chloramphenicol.
  32. MACROLIDES:Are a group of closely related compound characterized by macrocyclic lactone ring ( usually containing 14 to 16 atoms) to which deoxy sugar are attached. The prototyped drug is erythromycin Old Generation: Erythromycin, Oleandomycin, Troleandomycin, Spiramycin, Josamycin New Generation: Rosaramycin, Roxithromycin, Clarithromycin, Azithromycin, Dirithromycin
  33. MECHANISM OF ACTION: binds to the P site of the 50 S bacterial ribosomal subunit. Aminoacyl translocation and formation of initiation complex are blocked Inhibitory or bactericidal Activity is enhanced at alkaline pH.
  34. Resistance: is usually plasmid-encoded Reduced permeability of the cell membrane or active efflux production (by Enterobacteriaceae) of esterases that hydrolyze macrolides modification of the ribosomal binding site by chromosomal mutation Efflux and methylase production account for the vast majority of cases of resistance in gram-positive organism Cross resistance is complete between rythromycin and other macrolides
  35. SPECTRUM: Erythromycin has a narrow Gram (+) spectrum similar to Pen. G. Also active against Chlamydia and Legionella organisms
  36. Erythromycin prototype distributed into total body water poor CSF penetration food interferes with absorption serum half life is app. 1.5 h normally and 5 hours in patients with anuria not removed by dialysis metabolized in the liver traverses the placenta and reaches the fetus COMMERCIAL PREPARATIONS: Oral-stearate, ethyl succinate, estolate salts: 250-500 mg q 6 h . Esterates are acid resistant and better absorbed. Estolate best obsorbed. Parenteral- lactobionate, gluceptate : 0.5-0.1. g q 6 hours
  37. ADVERSE EFFECTS: GIT dysfunction, intrahepatic cholestatic jaundice (particularly the estolate preparation) erythromycin metabolites can inhibit cytochrome p450 enzymes & thus increase the serum concentrations of theophylline, oral anticoagulants, cyclosporine and methylprednisolone; also oral digoxin by increasing its bioavailability
  38. Clarithromycin Derive from erythromycin by addition of methyl group and has improved acid stability and oral absorption more active against Gram (+) pathogens, Legionella and Chlamydia than Erythromycin lower frequency of GIT effects, less frequent dosing advantage over Erythromycin half life of 6 hours given at 250-500 mg twice daily
  39. Azithromycin 15 atom lactone macrolide Derived from erythromycin by addition of a methylated nitrogen into the lactone ring Active against M. avium and T.gondii Less active than erythromycin and chlarithromycin against staph. and strep. More active against H. influenzae and chlamydia Penetrates into most tissues (except CSF) and phagocytic cells extremely well maintains high concentrations for prolonged periods into a number of tissues (lungs, tonsils, cervix) tissue half life – 2-4 days long half-life allows once daily oral administration and shortening of treatment in many cases ( a single 1 g dose of azithromycin is as effective as a 7 day course of doxycycline for chlamydial cervicitis and urethritis
  40. Community acquired pneumonia – 500 mg loading dose, followed by a 250 mg single daily dose for the next 4 days should be administered 1 hour before or 2 hours after meals; aluminum and magnesium delay absorption and reduce peak serum concentrations does not inactivate cytochrome p450 enzymes and free of the drug interactions that occur with erythromycin and clarithromycin
  41. CLINDAMYCIN / LINCOMYCIN MECHANISM OF ACTION: attach to 50 S ribosomal subunit, inhibits protein synthesis by interfering with the formation of initiation complexes and translocation reaction SPECTRUM: Has a Narrow Gram (+) spectrum, excellent activity against anaerobic bacteria; strep, pneumococci, staphylococci
  42. RESISTANCE: mutation of the ribosomal receptor site modification of the receptor by a constitutively expressed methylase enzymatic inactivation
  43. Clindamycin is more clinically used than Lincomycin given at 150-300 mg q 6 hrs adults ;10-20 mg/kg/d for children low concentration in CSF well bone penetration excreted mainly via the liver, bile and urine half life is 2.5 hours normally and 6 hours in patients with anuria more toxic than erythromycin
  44. Clinical uses: prophylaxis of endocarditis in patients with valvular heart disease for dental procedures most important indication is the treatment of severe anaerobic infection caused by bacteroides and other anaerobes that often participate in mixed infections + aminoglycoside or cephalosporin- used to treat penetrating wounds of the abdomen & gut, septic abortion, pelvic abscesses, aspiration pneumonia
  45. septic abortion, pelvic abscesses, aspiration pneumonia + primaquine – effective alternative to trimethoprim sulfamethoxazole for moderate to moderately severe Pneumocystis carinii pneumonia in AIDS patients + pyrimethamine for AIDS – related toxoplasmosis of the brain. ADVERSE EFFECTS: Diarrhea, nausea , skin rashes, impaired liver function and neutropenia Antibiotic associated colitis caused by toxigenic C. difficile.
  46. Quinuprisitn-Dalfopristin (Synercid) action is similar to macrolides except bactericidal for staph and most organisms except Enterococcus faecium prolonged postantibiotic effect up to 10 h for Staph. aureus administered IV at 7.5 mg/kg q 8 -12 h eliminated through fecal route, < 20% urine Patients with hepatic insufficiency may not tolerate the drug at usual doses inhibits CYP 3A4, which metabolizes warfarin, diazepam, astemizole, terfenadine, cisapride, nonnucleoside reverse transcriptase inhibitors and cyclosporine.
  47. Clinical Uses: infections caused by Vancomycin resistant strains of E faecium but not E. faecalis, bacteremia or respiratory tract infections caused by methicillin-resistant staphylococci and penicillin susceptible and resistant strains of S. pneumonia Toxicities: infusion related events, pain at the injection site, arthralgia, myalgia
  48. OXAZOLADINONES: Linezolid (Zyvox) inhibits protein synthesis by preventing formation of the ribosome complex that initiated protein synthesis. Its unique binding site located on 23 S ribosomal RNA of the 50 S subunit, results in no cross resistance with other drug classes Has high oral bioavailability, half life of 4-6 h Uses : staph, strep, enterococci, G(+) anaerobic cocci, G (+) rods, Corynebacterium, L. monocytogenes - treatment of infections caused by vancomycin resistant E. faecium and other infections caused by multiple drug resistant organisms.
  49. METABOLIC INHIBITORS Sulfonamides structural analogs of PABA competitively inhibit dihydropteroate synthase inhibits growth by reversibly blocking folic acid synthesis bacteriostatic
  50. Spectrum of activity: Inhibit the growth both Gm (+) and Gm (-) bacteria, Nocardia, Chlamydia trachomatis & some protozoa Enteric bacteria such as E.coli,klebsiella, salmonella,shigella, and enterobacter are also inhibited Rickettsia – not inhibited but growth stimulated by sulfas
  51. Resistance Mutation that cause overproduction of PABA Enzyme inactivation Loss of permeability to sulfonamides Resistant cells may be present in susceptible bacteria    
  52. Divided into Three Major Group Oral, absorbable a. Short acting – Sulfacytine, Sulfisoxazole, Sulfamethizole b. Intermediate acting – Sulfadiazine, Sulfamethoxazole, Sulfapyridine c. Long acting – Sulfadoxine   Oral, non absorbable – Sulfasalazine Topical – Sulfacetamide, Mafenide, Silver Sulfadiazine (burn victims)  
  53. topical a.Sodium sulfacetamide ophthalmic sol’n or ointment – for bacterial conjunctivitis b. Mafenide acetate- prevent bacterial colonization and infection of burn wounds c. Silver sulfadiazine –prevent of infection in burn wounds
  54. Pharmacokinetics Well absorbed from the GIT Widely distributed in the body including the CNS Highly bound to albumin Penetrate the CNS well Cross the placenta & secreted thru breast milk Acetylated ..retains toxic potential urine
  55. SPECTRUM: gram (+) & gram (-) Simple urinary tract infection - used short to medium acting agents like sulfisoxazole and sulfmethoxazole Ocular infection Burn infections Ulcerative colitis With pyrimethamine: Toxoplasmosis Malaria
  56. Adverse Reaction Hypersensitivity Reaction Photosensitivity Nausea & vomiting Hemolytic anemia Crysralluria & nephrotoxicity ( tx alkalinize the urine by NaHCO 3) sulfonamides ppt. at neutral or acid pH Kernicterus CI: Pregnancy & newborn DI: Compete with wafarin, tolbutamide, methotrexate for PPB
  57. TRIMETOPRIM SULFAMETHOXAZOLE ( CO-TRIMOXAZOLE ) COMBINATION CAUSES: 1. INCREASE POTENCY 2. INCREASE SPECTRUM 3. DECREASE INCIDENCE OF RESISTANCE MOA: blocks the sequential steps in the obligate enzymatic reaction in bacteria preventing formation of nucleotide
  58. Pharmacokinetcs Trimetoprim: more lipid soluble, greater Vd Given in 1: 5 ratio Uses UTI Pneumocystis carinii pneumonia (drug of choice) Shigellosis Systemic salmonella infection caused by ampicillin and chloramphenicol resistant-organism Some nontuberculous mycobacterial infection  
  59. Megaloblastic anemia Leucopenia Prevented by administration of folinic acid 6-8mg/day Granulocytopenia  
  60. NUCLEIC ACID SYNTHESIS INHIBITORS First Generation: Nalidixic acid Second Generation: Ofloxacin, Ciprofloxacin, Norfloxacin, Levofloxacin Third Generation: Gatifloxin, Sparfloxacin Clinafloxacin, Fourth Generation: Trovafloxacin, Moxifloxacin The newer generation has greater activity against gram positive organism
  61. Bactericidal Inhibits DNA Gyrase or Topoisomerase II - Block the relaxation of supercoiled DNA that is catalyzed by DNA gyrase Inhibits Topoisomerase IV – interferes with the separation of replicated chromosomal DNA during cell division
  62. Resistance Modification of DNA Gyrase Decreased accumulation in the bacterial cell due to : reduction of the porin proteins in the outer membrane energy dependent efflux system of the inner membrane
  63. Clinical Uses SPECTRUM: broad ; aerobic gm (+) & gm (-) but not anaerobes UTI Sexually transmitted diseases : Gonorrhea, Chlamydia, chacroid Prostatitis Respiratory infection due to H. influenza, M. catarrhalis, Strep pneumoniae, M. pneumoniae Norfloxacin is the least active against both gram + and gram – organism Second generation – ciprofloxacin, levofloxacin, = excellent gram – and moderate to good gram + activity
  64. CIPROFLOXACIN Most widely used DOC for anthrax Most potent for Ps, aeroginosa Synergististic with beta lactams M. tuberculosis NORfLOXACIN Not effective in systemic infection (fail to achieve systemic antibacterial level and least active agent for gram+ as well as Gram-
  65. LEVOFLOXACIN Prostatitis ,E. coli Sexually transmitted diseases, gonorrhea Skin & lower infections S. pneumoniae TROVA & MOXIFLOXACIN Anaerobes, P. AEROGINOSA GATIFLOXACIN Resp infection , S. pneuomoniae
  66. Side Effects Nausea & diarrhea Headache, dizziness, light headedness Arthralgia & joint swelling Rashes & photophobia
  67. CI: PREGNANT WOMEN, NEONATES ARRYTHMIAS: SPARFLOXACIN & MOXIFLOXACIN: prolong QT intervals DI: ↓ ABSORPTION WITH ANTACID , FeSo4 Cimetidine interferes elimination Ciprofloxacin & ofloxacin: ↑ theophylline levels